The iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB), SPDR S&P Biotech ETF (NYSEArca: XBI) and other biotechnology exchange traded funds were punished last year with election year rhetoric widely seen as the primary catalyst behind the sector's struggles. Healthcare stocks and ETFs rallied immediately following Republican Donald Trump's surprising November victory. The impact of a Trump… Click to read more at ETFtrends.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
This article was provided by our partner Tom Lydon of etftrends.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.